Originally published In Press as doi:10.1074/jbc.M202197200 on April 8, 2002
J. Biol. Chem., Vol. 277, Issue 24, 21549-21553, June 14, 2002
Interfacial Exclusion Pressure Determines the Ability of
Apolipoprotein A-IV Truncation Mutants to Activate Cholesterol Ester
Transfer Protein*
Richard B.
Weinberg
§¶,
Rachel A.
Anderson
,
Victoria R.
Cook
,
Florence
Emmanuel
,
Patrice
Denèfle**,
Alan R.
Tall
, and
Armin
Steinmetz§§¶¶
From the Departments of
Internal Medicine and
§ Physiology & Pharmacology, Wake Forest University School
of Medicine, Winston-Salem, North Carolina 27157, the
Cardiovascular Department, Gencell Division,
** Functional Genomics Center, Aventis Pharma, 94403 Vitry
sur Seine, France, the 
Department of
Medicine, Columbia University College of Physicians and Surgeons, New
York, New York 10032, and the §§ St. Nikolaus
Stiftshospital Teaching Hospital, University of Bonn, D-56626
Andernach, Germany
Received for publication, March 6, 2002, and in revised form, April 5, 2002
 |
ABSTRACT |
We used a panel of recombinant human
apolipoprotein (apo) A-IV truncation mutants, in which pairs of 22-mer
-helices were sequentially deleted along the primary sequence, to
examine the impact of protein structure and interfacial activity on the
ability of apoA-IV to activate cholesterol ester transfer protein.
Circular dichroism and fluorescence spectroscopy revealed that the
secondary structure, conformation, and molecular stability of
recombinant human apoA-IV were identical to the native protein.
However, deletion of any of the
-helical domains in apoA-IV
disrupted its tertiary structure and impaired its molecular stability.
Surprisingly, determination of the water/phospholipid interfacial
exclusion pressure of the apoA-IV truncation mutants revealed that, for most, deletion of amphipathic
-helical domains increased their affinity for phospholipid monolayers. All of the truncation mutants activated the transfer of fluorescent-labeled cholesterol esters between high and low density lipoproteins at a rate higher than native
apoA-IV. There was a strong positive correlation (r = 0.790, p = 0.002) between the rate constant for
cholesterol ester transfer and interfacial exclusion pressure. We
conclude that molecular interfacial exclusion pressure, rather than
specific helical domains, determines the degree to which apoA-IV, and
likely other apolipoproteins, facilitate cholesterol ester transfer
protein-mediated lipid exchange.
 |
INTRODUCTION |
Apolipoprotein A-IV is a 46-kDa plasma glycoprotein (1) that is
synthesized by the intestinal enterocytes of mammalian species (2)
during lipid absorption (3).
ApoA-IV1 enters circulation
as a component of nascent chylomicrons (4, 5), but rapidly dissociates
from their surface (5) and thereafter circulates primarily as a
lipid-free protein (6). A broad spectrum of physiologic functions has
been proposed for apoA-IV in human lipid metabolism (7, 8), including
specific roles in intestinal lipid absorption (8), intravascular
lipoprotein metabolism (9-12), cellular cholesterol efflux (13, 14) by
interaction with the ABCA1 transporter (15, 16), and regulation of the activity of two key proteins involved in the process of reverse cholesterol transport:lecithin-cholesterol acyltransferase (17, 18) and
cholesterol ester transfer protein (19, 20).
Cholesterol ester transfer protein (CETP) is a 74,000-dalton plasma
protein that facilitates the exchange of non-polar lipids among
circulating lipoproteins (21). CETP-mediated transfer of cholesterol
esters from HDL to very low density lipoprotein is central to
the process of reverse cholesterol transport (22). It is well
established that lipoprotein lipid composition modulates CETP activity
(23), but the role of apolipoproteins is less clear. In studies that
used lipid emulsions as model lipoproteins, apolipoproteins A-I, A-II,
A-IV, and E stimulated CETP-catalyzed lipid exchange equally well (20,
24, 25). However, studies that assayed CETP activity using native
lipoproteins found that apoA-IV may have distinct
concentration-dependant effects on CETP-catalyzed lipid exchange
between HDL and LDL (26) and among HDL subfractions (19, 27).
Although like all apolipoproteins, apoA-IV has a high content of
amphipathic
-helical structure (28, 29), the amphipathic helices in
apoA-IV are very hydrophilic (29), are predominantly of the Y-class
(30) and are incapable of deeply penetrating lipid monolayers (31, 32).
With increasing surface pressure, these helices are sequentially
excluded from the interface (33, 34). Consequently, the interaction of
apoA-IV with lipoproteins is very labile and is sensitive to
interfacial pressure (35). We have proposed that these properties
enable apoA-IV to act as a barostat which maintains lipoprotein surface
pressure within a critical range required for optimal activity of
lipolytic enzymes and transfer proteins (33, 36, 37). In this regard,
apoA-IV possesses dynamic interfacial properties that are optimal for stabilizing surface tension and lipid packing at expanding
lipid/aqueous interfaces (34).
Using a panel of recombinant human apoA-IV truncation mutants, Emmanuel
et al. (38) found that a specific
-helical domain located
between residues 117 and 160 determines the catalytic efficiency of
apoA-IV in the lecithin:cholesterol acyltransferase reaction. Given the
impact of distinctive
-helical domains in determining the
interfacial properties of apoA-IV, and given the importance of
interfacial phenomena in the regulation of the CETP reaction (36), we
have used this same panel of truncation mutants to examine the impact
of
-helical structure, protein conformation, and interfacial
activity on the ability of apoA-IV to modulate CETP-catalyzed
cholesterol ester transfer between HDL and LDL.
 |
EXPERIMENTAL PROCEDURES |
Lipids--
Egg phosphatidylcholine and cholesterol oleate
(Sigma) were dissolved in high performance liquid chromatography grade
chloroform (Aldrich, Milwaukee, WI) and stored under nitrogen at
20 °C. Phospholipid concentration was determined by phosphorous
analysis (39). The self-quenching fluorescent cholesterol ester analog NBDCE was obtained from Molecular Probes (Eugene, OR). Lipids were
>99% pure by TLC on silica gel.
Lipoproteins, Apolipoproteins, and Cholesterol Ester Transfer
Protein--
LDL and HDL were isolated from human plasma by sequential
flotation at 1.019-1.063 and 1.125-1.25 g/ml, respectively, and dialyzed against 10 mM Tris, pH 7.5, 100 mM
NaCl, 1 mM EDTA, 0.025% sodium azide. Human apoA-I was
isolated from HDL (40). Human apoA-IV was isolated from donors
homozygous for the A-IV-1 and A-IV-2 alleles (41). Recombinant human
apoA-IV truncation mutants were created by site-directed mutagenesis of
a DNA construct containing the human apoA-IV coding sequence, followed
by expression in Escherichia coli (38). Recombinant human
CETP was produced in a Chinese hamster ovary cell line expressing a
cloned human CETP cDNA; the specific activity of recombinant CETP,
as assayed by the transfer of 14C-cholesterol ester from
HDL to LDL, was identical to plasma CETP (42). Protein concentration
was determined with bicinchoninic acid (43). All preparations were
homogeneous by SDS-PAGE. Mean molecular hydrophobicities and helical
hydrophobic moments of recombinant apoA-IV truncation mutants were
calculated using a consensus hydrophobicity scale (44).
Circular Dichroism Spectroscopy--
Circular dichroism studies
were performed on a Jasco J-720 Spectropolarimeter. Spectra of
apolipoproteins at 3 µM in 50 mM Tris, pH
7.4, 1 mM EDTA, 0.02% sodium azide were recorded at
25 °C from 190 to 260 nm using a 1-mm thermostated cell, 1-mm
spectral bandwidth, and 2-s time constant. Buffer blanks were digitally subtracted. Percent
-helicity was calculated as previously described (28). Thermal denaturation studies were performed by monitoring ellipticity at 222 nm as a function of temperature from 20 to 65 °C.
The enthalpy of denaturation,
HD, and the thermal denaturation midpoint, Tm, were determined from the
slope of plots of
G versus 1/T
(45).
Fluorescence Spectroscopy--
Fluorescence studies were
performed on an SLM 8000C spectrofluorometer. Spectra of
apolipoproteins at 3 µM in 50 mM Tris, pH
7.4, 1 mM EDTA, 0.02% sodium azide were recorded at
25 °C from 290 to 370 nm using a 1-cm cell with excitation at 280 nm, 1-s integration, and 4-nm slits on excitation and emission
monochromators. Spectra were excitation corrected by reference to a
rhodamine quantum counter, and corrected for scatter and Raman emission by digital subtraction of buffer blanks. Chemical denaturation studies
were performed by addition of buffered 6 M guanidinium hydrochloride. Quenching studies were performed by addition of buffered
6 M KI; Stern-Volmer quenching constants,
Kq, were obtained from plots of
Io/I versus [KI];
fractional tryptophan exposure was calculated as
Kq(apolipoprotein)/Kq(N-acetyltryptophanamide) (46).
Determination of Interfacial Exclusion Pressure--
The
interfacial exclusion pressure (
ex) of recombinant
apolipoproteins at the phospholipid/water interface was determined using a KSV 5000 Langmuir Film Balance (KSV Instruments, Helsinki, Finland), as previously described (33, 36). Egg phosphatidylcholine monolayers were spread at the air/buffer interface at initial pressures
(
i) of 5-30 mN/m and then apolipoproteins were injected into the subphase to give a final concentration of 50 µg/dl, which had been previously determined to yield saturating binding to the
interface. The increase in interfacial pressure was then monitored by a
Wilhelmy plate until it reached a stable plateau (
).
ex was determined by extrapolation of 
versus
i. The precision of the interfacial
pressure measurements was ±0.1 mN/m.
Fluorescent Cholesterol Ester Transfer Assay--
Fluorescent
cholesterol ester transfer assays were performed using an SLM 8000C
spectrofluorometer equipped with a thermostated cell holder.
Recombinant HDL (rHDL) containing apoA-I, egg phosphatidylcholine, cholesterol oleate, and the self-quenching fluorescent cholesterol ester analog NDBCE were prepared by the method of Pittman et
al. (47). Reaction mixtures containing NBDCE-labeled rHDL (0.1 mg/ml), LDL (1 mg/ml), apolipoproteins (5 µM), and
recombinant human CETP (5 µg) in a final volume of 150 µl were
incubated at 37 °C in a 3 × 3-mm magnetically stirred
microcuvette, and the fluorescence intensity at 535 nm was monitored
for 30 min with excitation at 465 nm, a 1-s integration rate, and 4-nm
monochromator slits. Transfer rate constants were calculated from the
slope of a linear regression of time versus
ln(Imax
Ix), where
Imax is the maximal fluorescence intensity and
Ix is the fluorescence intensity at time X.
 |
RESULTS |
Calculated Hydrophobic Properties of Recombinant ApoA-IV Truncation
Mutants--
Recombinant human apoA-IV (r-AIV) and a panel of
recombinant apoA-IV truncation mutants in which pairs of 22-mer
-helices were sequentially deleted along the primary sequence from
the amino to carboxyl terminus were expressed in E. coli
(38). Although the calculated mean hydrophobicities, <H>,
and mean helical hydrophobic moments, <µ>, of the deleted segments
varied considerably, their deletion had a negligible impact on the
hydrophobic properties of the remaining molecule (Table
I).
View this table:
[in this window]
[in a new window]
|
Table I
Properties of the amphipathic helices in recombinant human apo A-IV and
recombinant apo A-IV truncation mutants
|
|
Spectroscopic Studies--
Circular dichroism spectra of r-AIV
revealed a mean residue ellipticity of 16,649 deg cm2/dmol
at 222 nm, which corresponds to 50%
-helical structure (Table
II). Thermal denaturation of r-AIV
yielded an enthalpy of denaturation,
HD, of 70.8 kcal/mol with a transition midpoint at 50.3 °C. These parameters are
similar to those obtained for native human apoA-IV-1 (28, 31, 45).
Likewise, fluorescence spectroscopy of r-AIV revealed several features
characteristic of human apoA-IV (28, 46). 1) The fluorescence emission
of its single tryptophan was blue shifted to 328 nm. 2) Tryptophan fluorescence was resistant to iodide quenching, indicating that the
tryptophan resides in a hydrophobic and/or negatively shielded environment. 3) Chemical denaturation induced a multiphasic red-shift in the wavelength of maximum fluorescence emission (data not shown) and
an increase in relative quantum yield
(Imax/Io) at the denaturation
midpoint (Table II). Together these findings suggest that the secondary
structure, conformation, and molecular stability of r-AIV are identical
to that of native human apoA-IV.
View this table:
[in this window]
[in a new window]
|
Table II
Spectroscopic and thermodynamic properties of human apo A-IV and
recombinant apo A-IV truncation mutants
|
|
ApoA-IV truncation mutants were much more sensitive to thermal
denaturation, as evidenced by
HD values that
were 19.6-51.0 kcal/mol lower than either native or the parent
recombinant apoA-IV. Interestingly the
-helicity of all the
truncation mutants was higher, perhaps reflecting recruitment of some
local secondary structure with disruption of ordered folding. The
tryptophan fluorescence emission in all the deletion mutants was
red-shifted compared with native and r-AIV, although iodide
accessibility was lower. Moreover, none of the truncation mutants
displayed the increase in quantum yield with denaturation that is a
signature of native human apoA-IV (28, 46). Taken together, these
findings demonstrate that deletion of any of the
-helical domains in
apoA-IV significantly disrupts its tertiary structure and impairs its
molecular stability.
Exclusion Pressure at the Lipid/Water Interface--
Examination
of the binding of r-AIV to egg phosphatidylcholine monolayers revealed
that r-AIV was excluded from the lipid/water interface at pressures
above 34.3 mN/m. In comparison, the exclusion pressure was 27.0 mN/m
for native human apoA-IV-1, 30.8 mN/m for native apoA-IV-2, and 33.0 mN/m for apoA-I, as previously noted (33). The higher interfacial
exclusion pressure of r-AIV relative to the native apolipoproteins
could be a consequence of the presence of a hydrophobic
MRGS(H)6 decapetide at its amino terminus, which was added
to the recombinant construct to facilitate purification (38).
Comparison of the interfacial exclusion pressure of the recombinant
apoA-IV truncation mutants with r-AIV yielded the surprising finding
that, with the exception of the
h1-2 and
h9-10 mutants,
deletion of amphipathic
-helical domains increased the interfacial
exclusion pressure (Fig. 1). There was no
consistent relationship between either the hydrophobic properties of
the excluded helices or the
-helicity of the remaining molecule and the interfacial exclusion pressure, although deletion of the
exclusively Y class helices (30) near the COOH terminus yielded
proteins with the highest surface activity.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
Difference in the water/phosphatidylcholine
interfacial exclusion pressure of recombinant apoA-IV truncation
mutants compared with the parent recombinant apoA-IV, for which the
exclusion pressure was 34.3 mN/m.
|
|
Effect on the Rate of CETP-mediated Cholesterol Ester
Transfer--
Incubation of NDBCE-labeled rHDL with a 10-fold excess
of LDL produced little change in fluorescence intensity; however, in the presence of CETP, transfer of the probe from the recombinant HDL to
LDL caused a rise in fluorescence emission. The transfer rate constant
in the presence of the common human apoA-IV-1 isoprotein was 2.22 × 10
3 s
1, for the variant human apoA-IV-2
isoprotein it was 2.59 × 10
3 s
1, and
for r-AIV it was 2.92 × 10
3 s
1. In
the presence of recombinant apoA-IV truncation mutants in the reaction
mixture, the transfer rate constant varied between 2.45 and 3.29 × 10
3 s
1. Multiple factor correlation
analysis identified no significant relationship between the transfer
rate constants and any of the spectroscopic parameters, but a strong
correlation was found between the transfer rate constants and
interfacial exclusion pressure (r = 0.790, p = 0.002) (Fig. 2).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Rate constant for the transfer of NBD-labeled
cholesterol esters from HDL to LDL versus interfacial
exclusion pressure for human apoA-IV-1, human apoA-IV-2, recombinant
apoA-IV, apoA-IV truncation mutants, and human apoA-I. The
regression line is y = 0.08696x 0.02111;
r = 0.790; p = 0.002.
|
|
 |
DISCUSSION |
In solution, apoA-IV adopts a loosely folded "molten globule"
conformation, in which the hydrophobic faces of its multiple amphipathic
-helices face inwards toward the interior of the molecule (28, 46). Our present findings demonstrate that these repeated
-helices collectively and cooperatively contribute to the molecular
stability of apoA-IV in solution, for deletion of even short helical
segments disrupts its tertiary conformation and significantly
destabilizes the molecule. This is further suggested by the observation
that these same deletions disrupt the otherwise strong self-association
of apoA-IV (38). Interestingly, conformational destabilization of
apoA-IV was associated with induction of additional
-helical
structure, probably as a consequence of coil
helix transformations
in regions of random coil structure, as occurs when it binds to
phospholipid vesicles (31), or possibly because of altered
self-association. Paradoxically, destabilization of the tertiary
structure of the apoA-IV truncation mutants increased their interfacial
exclusion pressure, perhaps because apoA-IV must unfold before it can
fully adsorb to lipid/water interfaces (31, 33), or perhaps because
destabilization of apoA-IV in solution increases the free energy
gradient for its adsorption to the hydrophobic interface.
The data from this unique panel of apoA-IV truncation mutants do not
support a role of specific helical domains in activating CETP. However,
the observation of a relationship between interfacial exclusion
pressure and cholesterol ester transfer rate sheds additional light on
the biophysical role of apolipoproteins in the CETP reaction. CETP
catalyzes the movement of non-polar lipids between lipoproteins along
chemical concentration gradients (21, 23). Apolipoproteins could
modulate this process by: 1) controlling the physical interaction of
CETP with the surface of acceptor and/or donor particles; 2) modulating
the interfacial solubility and accessibility of cholesterol esters; and
3) stabilizing acceptor particles as they acquire additional core lipids.
Regarding the first mechanism, the exclusion pressure of a lipid
transfer protein must be close to the pressure of donor and acceptor
interfaces, so that its binding is reversible; otherwise it could bind
too tightly and become "locked" on the interface. Indeed, the
calculated pressure of the HDL3 surface is 33 mN/m (33) and the
interfacial exclusion pressure of CETP is 31 mN/m (36). Thus,
apolipoproteins could control the association of CETP with donor and
acceptor lipoproteins by modulating surface pressure. For example,
there is little lipid transfer between naked lipid emulsion particles
with CETP alone (24, 25), for CETP binds tightly to both donor and
acceptor particles (48). The presence of apolipoproteins with exclusion
pressures higher than CETP enables it to dissociate from donor
particles after cholesterol ester loading, and, especially, from
expanding acceptor particles after cholesterol ester delivery. If such
phenomena predominate, then the efficacy of apolipoproteins in
activating or inhibiting CETP will be a function of both their
exclusion pressure and their ambient concentration (26).
Regarding the second and third mechanisms, both the microsolubilization
of membrane-free cholesterol and phospholipids (49) and the solubility
of cholesterol esters in phospholipid monolayers (36) is a function of
interfacial pressure. Thus, adsorption of apolipoproteins to acceptor
and donor particles could facilitate loading/unloading of cholesterol
ester molecules by optimizing their surface accessibility and buffering
any changes in the chemical concentration gradient as the reaction
proceeds. In this regard, the relationship between the interfacial
exclusion pressure of apoA-IV truncation mutants and cholesterol ester
transfer rate depicted in Fig. 2 is remarkably similar to the
relationship between exclusion pressure and the ability of
apolipoproteins to promote phospholipid efflux from free
cholesterol-enriched fibroblasts shown in Fig. 6 in the paper by
Gillote et al. (49). In addition, by reducing surface
tension, adsorption of apolipoproteins to acceptor particles would
minimize the free energy cost of expansion, analogous to the role of
the insect protein Lp-III in stabilizing hemolymph high density
lipophorin particles as they acquire diacylglycerol transported by the
lipid transfer particle (50). If such phenomena predominate, then the
efficiency with which apolipoproteins activate CETP will be directly
proportional to their surface activity (25).
Given that a large fraction of apoA-IV circulates as a lipid-free
apolipoprotein (6), and that both plasma apoA-IV levels (5, 51) and
CETP activity (52) increase in the post-prandial period, it is possible
that apoA-IV could modulate CETP activity in vivo. In this
regard, the higher exclusion pressure and cholesterol ester transfer
rate of the apoA-IV-2 isoprotein raise the question as to whether this
variant increases CETP activity in vivo. Several population
screening studies have observed lower HDL levels (53, 54), higher LDL
levels (55, 56), and an increased LDL/HDL ratio (54) in individuals
carrying an A-IV-2 allele, as would be expected with increased CETP
activity (57). However, in the only population survey to directly
measure CETP activity, von Eckardstein et al. (58) found
lower CETP activity in apoA-IV-1/2 heterozygotes. Possibly, other
apoA-IV genetic variants with altered interfacial properties (59) could
influence CETP activity.
Finally, these data raise several caveats regarding the use of modified
recombinant apolipoproteins in biological studies. First, they
illustrate how minor modifications made to facilitate protein
purification may have major structural and functional consequences. In
this case, addition of a hydrophobic decapeptide to the amino terminus
of the r-AIV construct significantly increased its surface binding
affinity and its ability to activate CETP. Second, these data
illustrate the need for a full biophysical characterization of
recombinant apolipoproteins used to probe the function of local
domains. Again, the amino-terminal modification of r-AIV appeared to
have no affect on its solution structure as assessed spectroscopically,
yet it had a major impact on its interfacial activity. Likewise,
spectroscopic characterization of the deletion mutants, alone, provided
no indication as to how their apparent structural destabilization could
increase their catalytic efficacy in the CETP reaction. Failure to
fully characterize the biophysical properties of modified recombinant
apolipoproteins could also lead to erroneously attributing a specific
biologic function to local structure, when in fact, it was determined
by global properties, such as interfacial activity. In this regard, however, comparison of our data and that of Emmanuel et al.
(38) supports their conclusion that helixes 5 and 6 (residues 117-160) in apoA-IV play a specific catalytic role in lecithin:cholesterol acyltransferase activation.
In summary using a panel of recombinant human apoA-IV truncation
mutants, we have found a strong correlation between interfacial exclusion pressure and the ability to activate CETP. We conclude that
molecular interfacial exclusion pressure, rather than specific helical
domains, determines the degree to which apoA-IV, and most likely other
apolipoproteins, facilitate CETP-mediated lipid exchanges.
 |
FOOTNOTES |
*
This work was supported in part by NHLBI National Institutes
of Health Grant HL30897 and American Heart Association Grant-in-Aid 93-013660.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Wake Forest
University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157. Tel.: 336-716-4638; Fax: 336-716-6376; E-mail:
weinberg@wfubmc.edu.
¶¶
Recipient of a Heisenberg-Stipendium from the Deutsche Forschungsgemeinschaft.
Published, JBC Papers in Press, April 8, 2002, DOI 10.1074/jbc.M202197200
 |
ABBREVIATIONS |
The abbreviations used are:
apo, apolipoprotein;
CETP, cholesterol ester transfer protein;
HDL, high density
lipoproteins;
LDL, low density lipoproteins;
NBDCE, 22-(N-(7-nitrobenz-2-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3b-linoleate;
r-AIV, recombinant human apoA-IV.
 |
REFERENCES |
| 1.
|
Weinberg, R. B.,
and Scanu, A. M.
(1983)
J. Lipid Res.
24,
52-59[Abstract]
|
| 2.
|
Weisgraber, K. H.,
Bersot, T. P.,
and Mahley, R. W.
(1978)
Biochem. Biophys. Res. Commun.
85,
287-292[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Hayashi, H.,
Nutting, D. F.,
Fujimoto, K.,
Cardelli, J. A.,
Black, D.,
and Tso, P.
(1990)
J. Lipid Res.
31,
1613-1625[Abstract]
|
| 4.
|
Green, P. H.,
Glickman, R. M.,
Saudek, C. D.,
Blum, C. B.,
and Tall, A. R.
(1979)
J. Clin. Invest.
64,
233-242[Medline]
[Order article via Infotrieve]
|
| 5.
|
Green, P. H.,
Glickman, R. M.,
Riley, J. W.,
and Quinet, E.
(1980)
J. Clin. Invest.
65,
911-919[Medline]
[Order article via Infotrieve]
|
| 6.
|
Bisgaier, C. L.,
Sachdev, O. P.,
Megna, L.,
and Glickman, R. M.
(1985)
J. Lipid Res.
26,
11-25[Abstract]
|
| 7.
|
Lefevre, M.,
and Roheim, P. S.
(1984)
J. Lipid Res.
25,
1603-1610[Medline]
[Order article via Infotrieve]
|
| 8.
|
Kalogeris, T. J.,
Rodriquez, M. D.,
and Tso, P.
(1997)
J. Nutr.
127,
537S-543S[Abstract/Free Full Text]
|
| 9.
|
Weinberg, R. B.,
and Spector, M. S.
(1985)
J. Lipid Res.
26,
26-37[Abstract]
|
| 10.
|
Weinberg, R. B.,
and Spector, M. S.
(1986)
Biochem. Biophys. Res. Commun.
135,
756-763[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Bisgaier, C. L.,
Sachdev, O. P.,
Lee, E. S.,
Williams, K. J.,
Blum, C. B.,
and Glickman, R. M.
(1987)
J. Lipid Res.
28,
693-703[Abstract]
|
| 12.
|
Goldberg, I. J.,
Scheraldi, C. A.,
Yacoub, L. K.,
Saxena, U.,
and Bisgaier, C. L.
(1990)
J. Biol. Chem.
265,
4266-4272[Abstract/Free Full Text]
|
| 13.
|
Steinmetz, A.,
Barbaras, R.,
Ghalim, N.,
Clavey, V,
Fruchart, J. C.,
and Ailhaud, G.
(1990)
J. Biol. Chem.
265,
7859-7863[Abstract/Free Full Text]
|
| 14.
|
Bielicki, J. K.,
Johnson, W. J.,
Weinberg, R. B.,
Glick, J. M.,
and Rothblat, G. H.
(1992)
J. Lipid Res.
33,
1699-1709[Abstract]
|
| 15.
|
Fournier, N.,
Atger, V.,
Paul, J. L.,
Sturm, M.,
Duverger, N.,
Rothblat, G. H.,
and Moatti, N.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
1283-1292[Abstract/Free Full Text]
|
| 16.
|
Remaley, A. T.,
Stonik, J. A.,
Demosky, S. J.,
Neufeld, E. B.,
Bocharov, A. V.,
Vishnyakova, T. G.,
Eggerman, T. L.,
Patterson, A. P.,
Duverger, N. J.,
Santamarina-Fojo, S.,
and Brewer, H. B.
(2001)
Biochem. Biophys. Res. Commun.
280,
818-823[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Steinmetz, A.,
and Utermann, G.
(1985)
J. Biol. Chem.
260,
2258-2264[Abstract/Free Full Text]
|
| 18.
|
Chen, C. H.,
and Albers, J. J.
(1985)
Biochim. Biophys. Acta
836,
279-285[Medline]
[Order article via Infotrieve]
|
| 19.
|
Lagrost, L.,
Gambert, P.,
Dangremont, V.,
Athias, A.,
and Lallemant, C.
(1990)
J. Lipid Res.
31,
1569-1575[Abstract]
|
| 20.
|
Main, L. A.,
Ohnishi, T.,
and Yokoyama, S.
(1996)
Biochim. Biophys. Acta
29,
17-24
|
| 21.
|
Tall, A. R.
(1993)
J. Lipid Res.
34,
1255-1274[Medline]
[Order article via Infotrieve]
|
| 22.
|
Bruce, C.,
Chouinard, R. A., Jr.,
and Tall, A. R.
(1998)
Annu. Rev. Nutr.
18,
297-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Lagrost, L.
(1994)
Biochim. Biophys. Acta
1215,
209-236[Medline]
[Order article via Infotrieve]
|
| 24.
|
Milner, T. G., Ko, K. W. S.,
Ohnishi, T.,
and Yokoyama, S.
(1991)
Biochim. Biophys. Acta
1082,
71-78[Medline]
[Order article via Infotrieve]
|
| 25.
|
Ohnishi, T.,
and Yokoyama, S.
(1993)
Biochemistry
32,
5029-5035[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Guyard-Dangremont, V.,
Lagrost, L.,
and Gambert, P.
(1994)
J. Lipid Res.
35,
982-992[Abstract]
|
| 27.
|
Barter, P. J.,
Rajaram, O. V.,
Chang, L. B. F.,
Rye, K. A.,
Gambert, P.,
Lagrost, L.,
Ehnholm, C.,
and Fidge, N. H.
(1988)
Biochem. J.
254,
179-184[Medline]
[Order article via Infotrieve]
|
| 28.
|
Weinberg, R. B.,
and Spector, M. S.
(1985)
J. Biol. Chem.
260,
4914-4921[Abstract/Free Full Text]
|
| 29.
|
Weinberg, R. B.
(1987)
Biochim. Biophys. Acta
918,
299-303[Medline]
[Order article via Infotrieve]
|
| 30.
|
Segrest, J. P.,
Jones, M. K., De,
Loof, H.,
Brouillette, C. G.,
Venkatachalapathi, Y. V.,
and Anatharamaiah, G. M.
(1992)
J. Lipid Res.
33,
141-166[Abstract]
|
| 31.
|
Weinberg, R. B.,
and Jordan, M.
(1990)
J. Biol. Chem.
265,
8081-8086[Abstract/Free Full Text]
|
| 32.
|
Weinberg, R. B.,
Jordan, M.,
and Steinmetz, A.
(1990)
J. Biol. Chem.
265,
18372-18378[Abstract/Free Full Text]
|
| 33.
|
Weinberg, R. B.,
Ibdah, J. A.,
and Phillips, M. C.
(1992)
J. Biol. Chem.
267,
8977-8983[Abstract/Free Full Text]
|
| 34.
|
Weinberg, R. B.,
Cook, V. R.,
DeLozier, J. A.,
and Shelness, G. S.
(2000)
J. Lipid Res.
41,
1419-1427[Abstract/Free Full Text]
|
| 35.
|
Weinberg, R. B.
(1992)
in
Third International Symposium on Plasma High Density Lipoproteins and Atherosclerosis
(Miller, N. E.
, and Tall, A. R., eds)
, pp. 89-98, Elsevier, New York
|
| 36.
|
Weinberg, R. B.,
Cook, V. R.,
Kussie, P.,
and Tall, A. R.
(1994)
J. Biol. Chem.
269,
29588-29591[Abstract/Free Full Text]
|
| 37.
|
Weinberg, R. B.,
Jones, J. B.,
Lacko, A. G.,
and Pritchard, P. H.
(1995)
Biochem. Biophys. Res. Commun.
211,
840-846[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Emmanuel, F.,
Steinmetz, A.,
Rosseneu, M.,
Brasseur, R.,
Gosselet, N.,
Attenot, F.,
Cuine, F.,
Seguret, S.,
Latta, M.,
Fruchart, J. C.,
and Denefle, P.
(1994)
J. Biol. Chem.
269,
29883-29890[Abstract/Free Full Text]
|
| 39.
|
Bartlett, G. R.
(1959)
J. Biol. Chem.
234,
466-468[Free Full Text]
|
| 40.
|
Shore, B.,
and Shore, V.
(1969)
Biochemistry
8,
4510-4516[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Weinberg, R. B.,
Hopkins, R. A.,
and Jones, J. B.
(1996)
Methods Enzymol.
263,
282-296[Medline]
[Order article via Infotrieve]
|
| 42.
|
Hesler, C. B.,
Swenson, T. L.,
and Tall, A. R.
(1987)
J. Biol. Chem.
262,
2275-2282[Abstract/Free Full Text]
|
| 43.
|
Smith, P. K.,
Krohn, R. I.,
Hermanson, G. T.,
Mallia, A. K.,
Gartner, F. H.,
Provenzano, M. D.,
Fujimoto, E. K.,
Goeke, N. M.,
Olson, B. J.,
and Klenk, D. C.
(1985)
Anal. Biochem.
150,
76-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Eisenberg, D.
(1984)
Annu. Rev. Biochem.
53,
595-623[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Weinberg, R. B.,
Anderson, R. A.,
Cook, V. R.,
Emmanuel, F.,
Denefle, P.,
Hermann, M.,
and Steinmetz, A.
(2000)
J. Lipid Res.
41,
1410-1418[Abstract/Free Full Text]
|
| 46.
|
Weinberg, R. B.
(1988)
Biochemistry
27,
1515-1521[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Pittman, R. C.,
Glass, C. K.,
Atkinson, D.,
and Small, D. M.
(1987)
J. Biol. Chem.
262,
2435-2442[Abstract/Free Full Text]
|
| 48.
|
Ohnishi, T.,
Hicks, L. D.,
Oikawa, K.,
Kay, C. C.,
and Yokoyama, S.
(1994)
Biochemistry
33,
6093-6099[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Gillotte, K. L.,
Zaiou, M.,
Lund-Katz, S.,
Anantharamaiah, G. M.,
Holvoet, P.,
Dhoest, A.,
Palgunachari, M. N.,
Segrest, J. P.,
Weisgraber, K. H.,
Rothblat, G. H.,
and Phillips, M. C.
(1999)
J. Biol. Chem.
274,
2021-2028[Abstract/Free Full Text]
|
| 50.
|
Ryan, R. O.
(1990)
J. Lipid Res.
31,
1725-1739[Medline]
[Order article via Infotrieve]
|
| 51.
|
Ostos, M. A.,
Lopez-Miranda, J.,
Marin, C.,
Castro, P.,
Gomez, P.,
Paz, E.,
Jimenez-Pereperez, J. A.,
and Perez-Jimenez, F.
(2000)
Atherosclerosis
153,
209-217[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Tall, A.,
Sammett, D.,
and Granot, E.
(1986)
J. Clin. Invest.
77,
1163-1172[Medline]
[Order article via Infotrieve]
|
| 53.
|
Kamboh, M. I.,
Iyengar, S.,
Aston, C. E.,
Hamman, R. F.,
and Ferrell, R. E.
(1992)
Hum. Biol.
64,
605-616[Medline]
[Order article via Infotrieve]
|
| 54.
|
Campos, H.,
Lopez-Miranda, J.,
Rodrigquez, C.,
Albajar, M.,
Schaefer, E. J.,
and Ordovas, J. M.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
1074-1081[Abstract/Free Full Text]
|
| 55.
|
Kamboh, M. I.,
Hamman, R. F.,
Iyengar, S.,
Aston, C. E.,
and Ferrell, R. E.
(1991)
Atherosclerosis
91,
25-34[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Von Eckardstein, A.,
Funke, H.,
Schulte, M.,
Erren, M.,
Schulte, H.,
and Assmann, G.
(1992)
Am. J. Hum. Genet.
50,
1115-1128[Medline]
[Order article via Infotrieve]
|
| 57.
|
Agellon, L. B.,
Walsh, A.,
Hayek, T.,
Moulin, P.,
Jiang, X. C.,
Shelansky, S. A.,
Breslow, J. L.,
and Tall, A. R.
(1991)
J. Biol. Chem.
266,
10796-10801[Abstract/Free Full Text]
|
| 58.
|
VonEckardstein, A.,
Funke, H.,
Chirazi, A.,
Chen-Haudenschild, C.,
Schulte, H.,
Schonfeld, R.,
Kohler, E.,
Schwarz, S.,
Steinmetz, A.,
and Assmann, G.
(1994)
Arterioscler. Thromb.
14,
1114-1120[Abstract/Free Full Text]
|
| 59.
|
Weinberg, R. B.
(2002)
Curr. Opin. Lipidol.
13,
125-134[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
V. M. Bolanos-Garcia, A. Renault, and S. Beaufils
Surface Rheology and Adsorption Kinetics Reveal the Relative Amphiphilicity, Interfacial Activity, and Stability of Human Exchangeable Apolipoproteins
Biophys. J.,
March 1, 2008;
94(5):
1735 - 1745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lu, Y. Yao, X. Cheng, S. Mitchell, S. Leng, S. Meng, J. W. Gallagher, G. S. Shelness, G. S. Morris, J. Mahan, et al.
Overexpression of Apolipoprotein A-IV Enhances Lipid Secretion in IPEC-1 Cells by Increasing Chylomicron Size
J. Biol. Chem.,
February 10, 2006;
281(6):
3473 - 3483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Weinberg, V. R. Cook, J. A. Beckstead, D. D. O. Martin, J. W. Gallagher, G. S. Shelness, and R. O. Ryan
Structure and Interfacial Properties of Human Apolipoprotein A-V
J. Biol. Chem.,
September 5, 2003;
278(36):
34438 - 34444.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.